Fortress Biotech (FBIO) Cash from Discontinued Operations (2018)
Fortress Biotech (FBIO) posted quarterly Cash from Discontinued Operations of 5737000.0 for Q4 2018, up 157.73% quarter-over-quarter from 2226000.0 in Q3 2018.
Powered by 
Analysis
Fortress Biotech (FBIO) Cash from Discontinued Operations (2018) Analysis & Trends
Fortress Biotech's Cash from Discontinued Operations history runs 1 years deep, the most recent figure standing at 5737000.0 for Q4 2018.
- In Q4 2018, Cash from Discontinued Operations changed N/A year-over-year to 5737000.0; the TTM figure through Dec 2018 stood at 1785000.0 (changed N/A YoY), while the FY2018 annual figure was 1785000.0, up 56.96% from the prior year.
- Cash from Discontinued Operations for Q4 2018 stood at 5737000.0, up from 2226000.0 in the prior quarter.
- The five-year high for Cash from Discontinued Operations was 5737000.0 in Q4 2018, with the low at 7367000.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | - |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 5.74 Mn |
| Sep 30, 2018 | 2.23 Mn |
| Jun 30, 2018 | -7.37 Mn |
| Mar 31, 2018 | -2.38 Mn |